Sanofi agreed a collaboration with AI biotech Earendil Labs worth $160 million upfront and near‑term to discover multiple bispecific autoimmune programs, with potential milestones lifting the deal to $2.56 billion and tiered royalties. Earendil will supply AI‑driven discovery and early optimization while Sanofi will develop and commercialize candidates globally. Separately, Servier tapped Insilico Medicine’s AI platform for early cancer R&D with up to $32 million in upfront and near‑term payments. Both pacts underscore big pharma’s appetite for AI‑driven candidate generation and signal continued outsourcing of discovery to specialist AI biotechs.